Insulin and insulin-like signaling regulate survival and lifespan in a variety of animal species, from nematodes and flies to higher vertebrates and mammals. Recently, it was shown that brain IGF-I receptor and brain IRS2 control mammalian lifespan, and that this occurs through neuroendocrine mechanisms, control of energy metabolism and modified stress resistance. Furthermore, it was demonstrated that insulin receptor substrate molecules are implicated downstream of insulin and IGF receptors in the extension of lifespan. We showed recently that early postnatal diet plays a significant role in the development of the somatotropic axis, and that part of the neuroendocrine plasticity of growth hormone secretion depends on postnatal nutrition. We also showed that the prevalence of cardiovascular and metabolic pathologies varied with the development of somatotropic function. Neuroendocrine pathways are also prime targets for pharmacological treatments, and administration of rapamycin to adult mice has indeed recently been reported to prolong lifespan in mice. With respect to human aging, new studies identified several genes of the somatotropic axis as longevity determinants, and a recent study shows that variants of FOXO3A, downstream signaling molecule in the insulin/IGF pathway, are associated with extreme longevity in humans. Finally, several functional mutations of the human IGF-IR have been discovered in centenarians.
process of biological aging is coordinated by the combined action of genes. On the molecular level, aging can be described as the sum of damages affecting all components of the cells, including DNA and other nuclear structures. Molecular changes due to aging are extremely diverse, although the underlying causes may be less complex. Aging is not a pathologic process and also clearly distinct from disease. However, numerous diseases are associated with age, and the many interactions between aging and disease considerably increase the complexity of aging phenotypes. A large number of premature or accelerated aging syndromes have been identified, and many have now been linked to mutations in genes participating in DNA maintenance and repair. These syndromes mimic physiological aging processes, generally in a segmental or partial manner. As in other domains, research into aging has been largely descriptive for many years, but more recently, experimental strategies to unravel genetics and molecular mechanisms of aging yielded tremendous progress. Much of this was initiated by studies using simple organisms, sufficiently small and short-lived so that screening for mutants with increased lifespan was possible. In the early 1990s, genes regulating survival and lifespan were identified in Caenorhabditis elegans, and their roles confirmed by mutagenesis in Drosophila [1, 2] . The majority of these longevity genes interact with each other, and it was shown that they are part of a major signaling pathway. The corresponding homologous pathways in vertebrate species and mammals were then identified as the cascades that regulate growth and metabolism, including the widely distributed receptors for insulin and IGF, and their respective substrates, the insulin receptor substrate (IRS) family of intracellular signal transducers. In the following years, results were swiftly transposed from nematodes to mammals, and today, numerous mouse strains with mutant insulin and IGF genes have been extensively studied with respect to aging and longevity.
Growth Hormone, IGF and Insulin Control Longevity in the Mouse
Strong increase in lifespan has been observed in mice with loss-of-function mutations of genes acting upstream of IGF receptor (IGF-IR), namely those implicated directly or indirectly in the neuroendocrine regulation of the somatotropic hormone (STH, or growth hormone -GH). This is the case for Prop1 and Pit-1, potent transcription factors regulating differentiation of cell lineages in the developing anterior pituitary. Both genes control the somatotrope cell population and thereby ultimately the production of GH in the adult pituitary. GH in turn stimulates the secretion of IGF-I, the cognate ligand of IGF-IR, during postnatal life and also in the adult organism. Inactivation of Prop1 and Pit-1 engenders a pan-hypopituitarism marked by drastic GH decrease. Very low GH in these mutants leads to up to 50% increase in mean lifespan, but also to radical changes in metabolism, growth and fertility [3, 4] . This rather broad phenotype can be attributed to the high degree of integration of neuroendocrine regulations that occurs in the hypothalamic-pituitary complex. Spontaneous mutation of GHRHR also significantly increases survival and lifespan [5] . Similarly, targeted mutations of the GH receptor (GHR), insulin receptor and IGF-IR were shown to increase the lifespan of mice [6] [7] [8] [9] . Downstream of these cell surface receptors, constitutive inactivation of p66Shc and IRS1, and the brain-specific knockout of IRS2 also increased lifespan [10] [11] [12] . This and other works confirmed that numerous components of the somatotropic hormone axis are involved in lifespan regulation. In addition to the above, it was also shown that somatotropic signals determine the resistance to oxidative stresses in several of these mutants. Research into aging in mammalian species has since focused on endocrine and neuroendocrine regulations of the somatotropic function.
Summarizing the above, three aspects are fundamental: (1) the implication of insulin and IGF signaling in lifespan regulation is strongly conserved during evolution, indicating that this trait is generally useful and important for survival; (2) in mammals, the principal regulator of lifespan is a hormonal signaling pathway that controls several vital processes; (3) the entire somatotropic hormone axis, which is the main regulator synchronizing growth and development in vertebrates, is involved in lifespan regulation.
Neuroendocrine Plasticity and Lifespan
Hormonal circuits and regulatory feedback allow individuals to adapt to changing environmental conditions through phenotypic plasticity. We showed recently in the mouse that it is sufficient to reduce the circulating levels of GH and IGF-I to postpone age-related mortality and increase lifespan [13] . For that we used the brain-specific heterozygous inactivation of IGF-IR, a conditional mutation that leads to a defect in somatotropic development shortly after birth. (In contrast, complete inactivation of IGF-IR specifically in the brain leads to microcephaly, profound retardation of pre-and postnatal development, and strong behavioral deficits.) The heterozygous knockout of brain IGF-IR, which produces a partial insensitivity of the brain for IGF-I signals, results primarily in a selective developmental defect of the somatotropic axis. In that mutant, the development of pituitary somatotropes is retarded; they secrete only a fraction of normal amounts of GH, and mutants show chronically low circulating IGF-I levels [13] . This occurs from shortly after birth onwards and causes a growth deficit phenotype. As adults, these mutants are slightly, but significantly smaller than control mice and their somatotropic tone is low. The reason for this GH-deficient phenotype resides in the hypothalamus, where low IGF stimulation inhibits the expression of Pit1, that later on leads to a diminished secretion of GHRH at the level of the median eminence. The resulting somatotropic insufficiency is characterized by strongly diminished GH release from the pituitary and low levels of GH-dependent serum markers like IGFBP-3 or ALS. This ultimately results in a lack of somatotropic stimulation in all peripheral target tissues. Importantly, the average lifespan of these mutants was significantly increased ( fig. 1 ), while growth was retarded and glucose metabolism moderately impaired [13] . Together with previous longevity phenotypes, these findings suggest that longevity in mutants with impaired GH and IGF signaling may be adaptive. As suggested above, neuroendocrine plasticity allows individuals to adjust growth and body size, but also metabolism and lifespan to environmental conditions, represented in the wild by the continuous fluctuations of natural resources. Such a mechanism requires individual developmental plasticity, in particular at the level of the somatotropic axis and the hypothalamic regulations. Previously, it had been shown in C. elegans and Drosophila that insulin-like signals in the nervous system can modulate the survival of the organism in a non-cell autonomous manner [14] [15] [16] [17] [18] [19] . Conditional IGF-IR gene targeting in the mouse CNS as described above confirmed that similar mechanisms exist in higher organisms. Interestingly, other neuroendocrine hormones regulated by the pituitary-hypothalamic complex, namely the gonadotropic, thyrotropic and adrenocorticotropic hormones, were unaffected, underscoring the specificity of this phenotype.
One of the consequences of GH deficiency in this mutant mouse was an increase in the size of subcutaneous adipose tissue (while all other tissues were slightly diminished in size). This is most likely a direct consequence of decreased GH action on energy metabolism in adipocytes, in particular via decreased lipolytic action, leading in fine to an altered lipid profile in serum. Furthermore, GH and IGF insufficiency produced slight glucose intolerance indicative of insulin secretory defect and peripheral insulin resistance. Since these metabolic traits are normally not associated with increased lifespan, other mechanisms must be involved in the observed increase in lifespan.
Early Postnatal Diet Conditions Adult Somatotropic Tone
Postnatal plasticity in neuroendocrine development of the somatotropic axis can also be triggered by modifications in early diet, namely by different levels of calorie restriction (CR) during the first weeks of postnatal development. This has recently been shown in our lab by Kappeler et al. [20] , who submitted newborn mice to different levels of restriction of mother's milk feeding. Underfeeding during the first 2 weeks of life significantly diminished the individual growth trajectory. More importantly, if underfeeding was limited to the milk feeding period and the same mice were fed ad libitum thereafter, they did not recover from the initial growth retardation and conserved the smaller body size for the rest of their life. The reason for limited catch-up growth, as we could show, is the particular hypothalamic-pituitary response initiated by dietary changes. Depending on mother's milk feeding in the neonates, their hypothalamus releases GHRH promoting the growth of somatotropes in the developing pituitary gland. After just 2 weeks of diminished (or increased) calorie feeding, substantial differences exist in terms of GH secretion and circulating levels of IGF. Importantly, these differences are not compensated during late development, but are progressively fixed during adult life of these animals. Kappeler et al. [20] could furthermore show that the extreme levels of somatotropic tone in adults (groups with very high, or with very low GH) were associated with hypertension, cardiovascular risk and metabolic dysregulation. Thus, it seems that early feeding pattern change the individual growth trajectory via differential regulation of the somatotropic axis, and that the particular individual neuroendocrine pattern can determine adult and late life pathology.
These experiments show that somatotropic development is highly plastic and that it is possible to inhibit this hormone axis efficiently on the level of the hypothalamus using targeted mutagenesis or dietary changes [13, 20] . Subsequent reduction in IGF and GH signaling not only extends the mean lifespan, but also diminishes the interindividual variability of lifespan to a considerable degree ( fig. 1 ). This raises the question why genetically identical wild-type mice (i.e. the control group) show a large interindividual variability in lifespan in the first place. We hypothesize that these differences in somatotropic development occur physiologically due to environmental factors that condition the individual neuroendocrine development and trajectories. Initially small stochastic differences are possibly amplified due to competition among siblings. Consequently, the individual rate of aging must be highly variable, too, depending on the individual's early life history. Yet, the role of insulin and IGF signaling in the brain goes beyond this regulation of the somatotropic tone, as has been illustrated by recent work by Taguchi et al. [10] looking into the phenotypic consequences of IRS2 knockout specifically in the brain. These authors made heterozygous and homozygous brain-specific IRS2 knockout mutants and found significantly increased lifespan in both of them. The heterozygous bIRS +/-mutant showed in addition to that an enhanced glucose tolerance and sensitivity to insulin. Both mutants had increased adult bodyweight later in life due to an increasing amount of fat tissue. Body length was normal in the longlived heterozygous mutant, but resistance to oxidative stress was increased under certain conditions [10] . Comparing brain-specific inactivation of IGF-IR and IRS2, it appears that both genotypes generate an overlapping, but also different hypothalamic pattern of metabolic changes, stress resistance phenotype and longevity ( fig. 2) . Together, these findings suggest that metabolic regulations may play a more salient role in the longevity of neuroendocrine origin.
Treatments That Extend Lifespan
Long before genes modifying aging and longevity were discovered, CR was used as an efficient means to prolong the lifespan of rodents. Maximum effects were obtained with restriction to about 50% of ad libitum dietary intake, which is just enough to prevent malnutrition. CR strongly diminishes insulin secretion and also reduces the circulating IGF-I levels. However, the relationship between IGF and insulin signaling, CR, and aging is still not very clear. Some studies conclude that pathways responsible for CR-induced longevity are not identical to insulin and IGF pathways or only partially overlap [21] , while other reports conclude that somatotropic signals are essential for relaying the lifeprolonging effects of CR in mice [22] . Whatever is more pertinent, insulin sensitivity appears to be a major factor influencing longevity in laboratory rodents. Finally, somatotropic signaling cascades offer multiple targets for pharmacological inhibition. mTOR (mammalian target of rapamycin), a regulator of cell proliferation and cell survival, is one of them, and recently a large study administrating rapamycin in adult mice demonstrated that chronic treatment with rapamycin can extend their lifespan [23] . It is possible that some of the positive effects on survival are due to decreased IGF action; however, rapamycin also affects several other pathways that may influence lifespan through alternative mechanisms. It is tempting to test this substance as a potential inhibitor of aging in humans, but rapamycin acts also as an immunosuppressor that may produce unwanted effects under long-term treatment.
Somatotropic Hormones and Human Longevity
Research into longevity using distant species showed that a conserved set of homologous genes control lifespan throughout evolution. These genes are part of the endocrine system in higher vertebrates, and an obvious question is whether they are also implicated in human longevity. While most of the available results in this area are descriptive, and some of them merely circumstantial, other findings allow cautious extrapolation to human aging. There are several reports on human growth and aging that suggest a negative correlation between mean body height and life expectancy. Such effects, however, if they exist in human populations, are currently more than compensated, e.g. by constant amelioration of hygiene, nutrition, health care and disease prevention. Under modern living conditions, average body length and life expectancy generally increase in parallel, a fact that masks any underlying reciprocal relationship. Meanwhile, several genetic studies show a correlation between human lifespan and variants of alleles that modify insulin and IGF signaling [24, 25] . One of these studies showed in a prospective cohort of aged females that certain alleles of GH, IGF-I and IRS-1 predict shorter adult body length and at the same time correlate with better survival at an advanced age [25] . In that study, GH gene variants alone explained a 2 cm lower body height and a significant increase in late life survival. Moreover, in early 2008, Suh et al. [26] reported several non-synonymous mutations that they had identified in a human population of centenarians [26] . Both mutations affected functionally relevant domains of the IGF-IR molecule and were therefore serious candidates that could affect IGF signaling and human longevity. When the authors extended their research to a larger cohort, they found more carriers for the mutation among those with exceptional longevity, but also one carrier in the control population. This suggests that functionally relevant mutations in the IGF-IR gene may help to survive until an advanced age, but that such mutations are not sufficient to ensure longevity. These authors also found additional typical traits of IGF-IR inactivation in the group of carriers of these mutations, i.e. reduced mean body height (measured at the time they were young adults) and increased circulating IGF-I. It is of interest that in acromegalic patients persistently high circulating levels of IGF-I are a strong predictor of premature death [27] , and that high circulating IGF-I in elderly people is correlated with increased mortality [28] . Historically, life expectancy of acromegalic patients suffering from pituitary gigantism (nowadays treated early to prevent pathological growth) was severely diminished compared to the normal population. Finally, another recent study found that allelic variants of FOXO3A, a transcription factor acting downstream of the GH/IGF-I pathway, are associated with increased longevity in a Japanese cohort of male centenarians [29] . These findings were confirmed and extended using a large group of centenarians from Germany. Certain polymorphisms of FOXO3A were again associated with very old age, and this association increased from nonagenarians to centenarians [30] . This was true for both sexes, and the authors were able to reproduce their results in a French cohort of centenarians, where a similar trend prevailed. Collectively, this indicates that FOXO3A is susceptible to act as a longevity gene in humans.
Taking all this evidence together, it appears that it is more important than ever to intensify the study of the role of nutrition and somatotropic signaling in human health and longevity, and to further develop knowledge-based counseling with respect to early diet, growth regulation and human aging.
Discussion
Dr. Stettler: For those of us who don't work with mice, can you tell us what mice die of when they get old, the same diseases as humans or different diseases?
Dr. Holzenberger: The panel of pathologies in aged mice depends on the mouse strain. We are working with F1 hybrid strains that show a large spectrum of diseases. They die of cancer, infections, cardiovascular diseases or degenerative diseases. Some mouse strains die of just a few specific diseases. So, the answer is yes, mice die of essentially the same large variety of age-related diseases as humans.
Dr. Stettler: So those are closer to humans, and if I understood correctly in your experiment where you underfed and overfed both, the overfed and the underfed had metabolic and cardiovascular risk factors. But despite those cardiovascular risk factors, the ones that were underfed did live longer, so what did they die of? Did they not die of the cardiovascular disease and metabolic disease?
Dr. Holzenberger: It is not easy to answer that question because statistics on endof-life pathologies cannot be established routinely. We handle about 15-20 mice per group, and statistical power in terms of pathology at the time of death is low at that sample size. To perform valid statistics on pathology, we would need 100 or more individuals per group. So, concerning the glucose intolerance that these mice display, it may well be that they sense their metabolic problems and that they respond with altered feeding behavior, and thereby avoid complications. But we do not have definite proof of that.
Dr. Klish: Every time I hear an aging talk like this, I get depressed. As the tallest man in this room and possibly the oldest man in this room, do you have any hope for me?
Dr. Holzenberger: Every time I give an aging talk I get this question, so, yes, there are exceptions to the rule.
Dr. Fasano: I guess that we are taller and bigger than our grandparents and our great-grandparents because we stimulate this growth hormone-insulin IGF axis. On one hand we grow better because we have more nutrients, but we are giving up that 20% 'buffer zone' when we push this pathway to its limits. And related to that, I have a very good friend of mine who has been devoting his science to the positive impact of limited calorie intake on longevity, and he insists that if I eat 1,500 calories or less, I will live 6 years longer. So, you put in question the findings in primates.
Dr. Holzenberger: The case of the primate is not settled, since there are contradictory results. The specific problem with aging studies in primates is that they are very long-term studies, lasting over 40-50 years. And I must confess that I am myself not on dietary restriction. Today, there is also less consensus than before on the links between dietary restriction and longevity, also because of recent work where about 40 mouse strains have been submitted to dietary restriction [1] . That work revealed that only a few of the tested strains responded positively with extended lifespan, while many others did not. Specifically, those strains that were naturally long lived did not further extend lifespan under dietary restriction, but some of the short lived did. So, somehow there must have been a selection of the mouse models that researchers used for dietary restriction experiments in the past. In other terms, not every mouse strain responds positively to dietary restriction, and we hypothesize that there are modifier genes for the dietary restriction phenotype. To my thinking, it is too early to decide on whether dietary restriction works in humans, and we still have to find out what the conditions are under which humans would respond to caloric restriction with some extra years.
Dr. Fasano: What about the human evolution? Dr. Holzenberger: Due to the mechanisms that I described in the mouse, we observe a secular growth trend in humans, with increasing body size and body frame over the last 200 years, in all developed countries, but we do not know what this does to life expectancy. Of course, life expectancy has increased in all developed countries, and this is due to what I showed at the very beginning with the human survival curves. We not only eat more and grow faster, but we have also much better health care, hygiene, etc., and life is generally healthier and that makes us live longer. But there may be an undercurrent in all this: although we already live longer than before, we could live even longer than that. If you think of how very old people look like, those who reach 100 years, they are rather small people, and this does not seem to be loss of body mass during aging, but a smaller body frame from the beginning. So, I think we should listen to the few studies in human populations that demonstrated that a lower body size is correlated with increased lifespan. Obviously, more systematic studies need to be performed.
Dr. Haschke: To follow up on your comment, this 'US hunger study' in healthy adults is described in one of the Nestlé Nutrition Workshop books. The volunteers reacted to long-term caloric restriction with depression, but all metabolic parameters -such as insulin sensitivity improved further even in healthy adults. My question to you is: are there any data on life expectancy in IGF-I-deficient populations?
Dr. Holzenberger: There are very few people with IGF deficiency, in terms of mutations?
Dr. Haschke: Yes, but in the meantime the IGF-I treatment (for children with short stature who don't react to growth hormone treatment) has become a business. My question is: are there any reliable data on morbidity and life expectancy of those cohorts? Or are there data on Pygmies?
Dr. Holzenberger: It may be difficult to conclude from data on Pygmy populations since their survival relates very much to their particular environment. But there are growth hormone-deficient humans with mutations in either the growth hormone gene or its receptor. Still, the results are contradictory. A new study on GH-deficient men and women from Ecuador reports that there is no difference in terms of lifespan. However, these people are protected from cancer and diabetes [2] . At the same time, they show a high mortality related to alcohol abuse and accidents. One may speculate that if their lifestyle would not expose them to these killers, then the protective effect of growth hormone deficiency could be more penetrant. To my thinking, it is possible that in humans some form of growth hormone deficiency may increase life expectancy, but we cannot directly transpose findings from animal studies to humans.
Dr. Lack: So, if you had a small child, would you allow your child to get growth hormone replacement, and are there any issues there? Secondly, where does exercise fit into this model, so what happens to athletes like Olympic swimmers or boxers who eat huge amounts of calories, have huge muscle mass, do they die earlier?
Dr. Holzenberger: There are few studies on that, not very systematic though, on athletes with larger body size, and they do have significantly shorter lifespan. Growth hormone abuse is a major risk factor in this context. Then, there are patients who have been long-term substituted with growth hormone, and those who displayed high GH levels under substitution had indeed an increased mortality later on. So, there are some indications but not yet sufficiently large and prospective studies, but there will certainly be more data due to the growth hormone that is sold over the internet, and the many people using it without prescription. This will create a huge amount of data in the future.
Dr. Simmer: I wanted to ask you about gender differences. I noticed on one of your slides that in the IGF mice the males lived 100 days longer, but it didn't seem to have any effect on the females.
Dr. Holzenberger: There is a lot of sex dimorphism in longevity studies studying insulin and IGF signaling, and we don't know the reasons for that yet. In the first mutant mouse that I showed, we see significant lifespan extension in the females and only half the effect in males, and this latter effect was actually not significant. We repeated this with a slightly different mutant, which leads to just 30% inactivation of IGF receptor. Under these conditions, we see significant lifespan extension in the males and not in the females. So, somehow there seems to be a dose-response relationship that is sex dependent, suggesting that what is good for females in terms of lifespan extension is may be not good for males, and vice versa. From the last data that I showed you, the ones on early postnatal diet, it should be clear that the effect exists in males and not in females, so there is also a sex dimorphism, but for the time being we do not have sufficient data to say something about the underlying mechanisms.
Dr. Mohanty: Our observation is that postmenopausal women do much better than men, and they live longer than men. Importantly, I was involved in a small experiment in London that was about infection and nutrition in animal models. We injected the malarial parasite Plasmodium berghei berghei to the rats that were fed different protein levels. We found that the rats fed higher levels of protein developed jaundice, got very sick and died very early, whereas those on low levels of casein recovered from the disease, had a longer life, and were fine. So in that context, were the animals in your model more resistant to infection because of the restricted diet and that's why they lived longer, or is there some other explanation?
Dr. Holzenberger: Maybe I'll start with infectious disease, or better: the resistance to infectious disease. In these mice, if we use different stressors, and that can be paraquat, paracetamol, diquat, or hyperoxia, we observe better survival in the mutants. So, there must be a rather broad protection from a variety of stresses, and this may be due to p66Shc signaling or FOXO signaling that in turn regulate many other downstream genes involved in stress resistance. Whether this has impact also on resistance to infectious disease, I cannot say, we would need to inoculate them with a suitable agent. This relates to the question about pathologies later in life, and although we did not obtain significant results so far, we see that specific disease categories and multimorbidity are reduced in mice with reduced IGF and growth hormone signaling. So, it could well be that the infectious diseases are less of an issue in these mutant mice than in the controls.
Dr. Harding: What would be of most interest in terms of effects in humans would be to follow up the randomized trials of growth hormone treatment of growthrestricted children. Growth-restricted children grow slowly and have low IGF-I levels, and quite a lot of them have been treated in randomized trials with growth hormone. So, they would be an interesting group to look at to answer the question.
Dr. Holzenberger: We should make a distinction between those who received growth hormone treatment because they are severely growth hormone deficient, and others who do not have such clear indication for treatment. Also, some adults with significant growth hormone deficiency should be candidates for hormone substitution. More problematic are those cases where parents come to the pediatrician and seek growth hormone treatment for children who are not even 2 standard deviations below the mean of their age group. In these cases, the indication is more facultative, and negative potential side effects in terms of possible reduction of lifespan must be taken into consideration. So, I think one should make a distinction between clearly pathological cases of growth hormone deficiency and growth retardation that need treatment, and those cases where this is more an elective treatment chosen to enhance pubertal growth. Those children are often within the normal range of body size for age, and thinking about our mouse studies, it should be taken into consideration that there may be significant effects on longevity. Within this group, I would recommend to be very prudent with growth hormone therapy. In practice, the decision will be left with the parents, who clearly need full and unbiased information about growth, hormones and effects on longevity.
Dr. Harding:
My question was about the rather intriguing data you presented about both the increased and decreased feed groups having similar metabolic phenotypes but different longevities. There is evidence of a J-shaped relationships between size and many metabolic phenotypes in the epidemiological studies, and I just wondered if you or anybody else in the room knows of any evidence that there are in fact those two populations in the human studies? In other words, have we got two populations of adults with metabolic disease, only one of which is actually going to die from this?
Dr. Stettler: There is an increasing literature on healthy obese, and I think that may be what you are talking about. There is a sub-category of people who are obese but seem to be metabolically OK.
Dr. Harding: I was really referring to the people who have metabolic abnormalities, but only some of whom are actually going to get into trouble with these. If the mice studies are relevant to the human, I think it would be interesting to think further about that in terms of the epidemiology.
Dr. Shreffler: Are there inducible knockouts in genes that would be helpful for exploring these pathways in adults?
Dr. Holzenberger: We are indeed switching to inducible models, because as I showed there are developmental defects due to the lack of IGF receptors during development. For instance, in the IGF-IR knockout targeted to the forebrain neurons, if we do that in an inducible manner, we obtain the same neuroendocrine response and phenotype, proof that there is acute endocrine regulation. Therefore, it appears that there is neuroendocrine feedback that leads to increased somatotropic tone. The interesting question then is, can we have a negative effect on life expectancy in this model when we trigger growth hormone oversecretion late in life. Then, we may also address the question whether we observe acute effect on survival or whether these are long-term effects of high growth hormone and high IGF-I.
Dr. Klish: The other side of aging research has to do with programmed cell death, apoptosis and what controls it. Do you have any knowledge within your models as to what is happening to that side of the aging process?
Dr. Holzenberger: I apologize, I have no data that could answer this question.
